The challenge of bacillus calmette-guérin failure in nonmuscle invasive bladder cancer - What is the next step in management?

Journal of Urology

Volumn 190, Issue 3, 2013, Pages 832-833

  Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BCG VACCINE; DOCETAXEL; GEMCITABINE; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 8; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P53; VALRUBICIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CELLULAR IMMUNITY; COMORBIDITY; COST CONTROL; CYSTECTOMY; DISEASE COURSE; DNA REPAIR; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE PRODUCT; GENE THERAPY; GENETIC MARKER; HUMAN; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LAMINA PROPRIA; LYMPH VESSEL METASTASIS; MAINTENANCE THERAPY; PATIENT CARE; PATIENT COUNSELING; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOBLASTOMA; SALVAGE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR INVASION;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROGNOSIS; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84881481620     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.030     Document Type: Editorial

References (12)

1. D.R. Yates, M.A. Brausi, J.W. Catto Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer Eur Urol 62 2012 1088
2. S. van den Bosch, J.A. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493
3. G.S. Kulkarni, S.M. Alibhai, A. Finelli Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer Cancer 115 2009 5450
4. J. Fernandez-Gomez, E. Solsona, M. Unda Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992
5. A.M. Kamat, R.J. Dickstein, F. Messetti Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial J Urol 187 2012 862
6. T.C. Zuiverloon, A.J. Nieuweboer, H. Vékony Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review Eur Urol 61 2012 128
7. G. Steinberg, R. Bahnson, S. Brosman Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder The Valrubicin Study Group J Urol 163 2000 761
8. P. Gontero, M. Oderda, A. Mehnert The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial J Urol 190 2013 xxx
9. G. Jones, A. Cleves, T.J. Wilt Intravesical gemcitabine for non-muscle invasive bladder cancer Cochrane Database Syst Rev 1 2012 CD009294
10. R.J. Lammers, J.A. Witjes, B.A. Inman The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review Eur Urol 60 2011 81
11. B.L. Gallagher, F.N. Joudi, J.L. Maymí Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy Urology 71 2008 297
12. Z. Tao, R.J. Connor, F. Ashoori Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation Cancer Gene Ther 13 2006 125